This site is intended for healthcare professionals
Drug news

Data from phase III trial of Sublocade in opioid use disorder published in Journal of Addiction Medicine

Read time: 1 mins
Last updated:11th Mar 2019
Published:8th Mar 2019
Source: Pharmawand

Indivior announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication satisfaction, employment, health insurance status and healthcare resource utilization) of Sublocade (buprenorphine extended-release) injection for subcutaneous use in opioid use disorder by the Journal of Addiction Medicine. These measures were collected during the 24-week, Phase III, randomized, placebo-controlled study assessing the drug's efficacy, safety and tolerability.

The results showed that participants receiving Sublocade versus placebo experienced significant changes from baseline on the EQ-5D-5L index (300/300mg: difference=0.0636) and visual analog scale (300/300mg: difference=5.9, 300/100mg: difference=7.7), and on the SF-36v2 physical component summary score (300/300mg: difference=3.8; 300/100mg: difference=3.2). Treatment satisfaction was significantly higher at the end of study for participants receiving Sublocade 300/300mg and 300/100mg than placebo. Employment increased by 10.8% with Sublocade 300/300mg and 10.0% with 300/100mg but decreased by 12.6% with placebo. Participants receiving Sublocade compared with placebo had significantly fewer hospital days per person-year observed.

See: "Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study." Ling W et al. J Addict Med. March 2019 DOI:

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.